The Global mRNA Vaccine & Therapeutics Raw Material Market was Worth USD 37.53 Billion in 2021 and it is Expected to Reach USD 84.74 Billion at the End of 2028 with a CAGR of 12.34%.
mRNA has been on clinical trial for a decade, and it is being used in various research and development projects. But various factors like less proven facts, fear of getting misused as a bioweapon, and others have forced mRNA to remain behind the curtain. So, till now mRNA has been used only for R&D purposes and numerous companies have invested millions of dollars in various products which are under clinical trials. As result, no mRNA product has been commercialized in the global vaccine & therapeutics market.
But the sudden panicking situation created by the coronavirus outbreak has called for every kind of technology we can use against Covid-19. Even if mRNA had never been used against any disease but scientists did have years of research on RNA technologies including mRNA which is why scientists were able to start testing practices against Covid-19 so quickly.
mRNA has been never created on large scale due to which there were no dedicated production plants for mRNA-based products nor for raw materials and a sudden spike in demand has created various challenges across the supply chain for mRNA-based vaccine manufacturers, raw material suppliers, logistic players &, etc. But to tackle this challenge numerous companies have shifted their cash flow towards mRNA production.
Jena Bioscience is a biotechnology company in Jena, Germany, Jena Bioscience was established in 1998 by a team of scientists from the Max-Planck-Institute of Molecular Physiology (Dortmund), Jena Bioscience utilizes more than 25 years of academic know-how to develop innovative reagents for clients from both research and industry in 100+ countries. To date, Jena Bioscience still remains an owner-operated business.
The Jena Bioscience Company had nearly 26 Employees and had a revenue of USD 6 Million.
Thermo Fisher Scientific Inc. is an American supplier of scientific instrumentation, reagents and consumables, and software services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006.
The Thermo Fisher Scientific Inc. Company had nearly 55,000 employees and had a revenue of USD 40 Billion.
Beijing SBS Genetech Co., Ltd. is one of the earliest Chinese companies providing scientific solutions for biological scientists and researchers, starting from custom oligonucleotide synthesis, gene synthesis, and custom peptide synthesis. Since we were founded in 2000. The company served top researchers in nearly 60 countries, empowering them to create new fundamental knowledge in the field of biology.
The SBS Genetech Company had nearly 500 employees and had a revenue of USD 49 Million.
Lucigen is a leading developer, manufacturer, and supplier of molecular biology enzymes, reagents, and kits. Lucigen company was founded in 1998 and is headquartered in Middleton, Wisconsin, United States. The company manufacture and sell over 325 biomedical research products and services to customers worldwide.
The Lucigen Company had nearly 35 employees and had a revenue of USD 18 Million.
Sigma-Aldrich (formally Millipore Sigma) is an American chemical, life science, and biotechnology company that is owned by the German chemical conglomerate Merck Group. Sigma-Aldrich was created in 1975 by the merger of Sigma Chemical Company and Aldrich Chemical Company. The company is headquartered in St. Louis and has operations in approximately 40 countries.
The Sigma Aldrich Company had nearly 20,000 employees and had a revenue of USD $2.7 Billion.